{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:44:17Z","timestamp":1793241857776,"version":"4.5.0"},"reference-count":187,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Eczema is an inflammatory skin condition that affects individuals of all ages worldwide. Patients may develop various forms of eczema, including atopic dermatitis, contact dermatitis, which is often associated with an allergic response to various stimuli, dyshidrotic eczema which develops on the palms and soles, asteatotic dermatitis that predominantly occurs in elderly patients, nummular eczema characterized by its cylindrical shape lesions and seborrheic dermatitis often located on patient's scalps, back, face and chest. Extensive studies have been conducted on atopic dermatitis, however, limited information such as their etiology, effect on the immune system and potential treatments are available on the other types of eczema. The socioeconomic impacts of eczema include the cost of conventional treatments such as corticosteroids, immunosuppressive agents and phototherapy, expenses related to specialists\u2019 consultation and the effect on work and school productivity. The impact of atopic dermatitis on patients\u2019 quality of life, social functioning and individual healthcare expenses has been extensively studied in other countries but remains underreported in South Africa. Reports have estimated the annual direct and indirect costs in Australia, the United Kingdom and the United States, however reports are limited for South Africa. This study aimed to provide information on the different types of eczema's etiology, their respective socioeconomic impact in South Africa in correlation to the above mentioned inflated yearly cost, and conventional, targeted and alternative treatments commercially available. Several knowledge gaps were identified in this study, including the limited availability of information on asteatotic dermatitis, dyshidrotic dermatitis and nummular eczema, the effect most commercially available treatments have on other eczema subtypes and an in-depth review of the socioeconomic impact of eczema within the African continent.<\/jats:p>","DOI":"10.3389\/falgy.2025.1675475","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:17:23Z","timestamp":1768205843000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Eczema: etiology, subtypes, therapeutic approaches and socioeconomic impact"],"prefix":"10.3389","volume":"6","author":[{"given":"Mariz\u00e9","family":"Cuyler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Twilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrita","family":"Lall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jaci.2006.03.045","article-title":"Diagnosis and treatment of atopic dermatitis in children and adults: european academy of allergology and clinical immunology\/American academy of allergy, asthma and immunology\/PRACTALL consensus report","volume":"118","author":"Akdis","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B2","first-page":"1","article-title":"Epidemiology of skin diseases from the spectrum of dermatitis and eczema","volume":"29","author":"Dorynska","year":"2012","journal-title":"Malays J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3390\/life11090936","article-title":"The epidemiology and global burden of atopic dermatitis: a narrative review","volume":"11","author":"Hadi","year":"2021","journal-title":"Life"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/j.1468-3083.2010.03655.x","article-title":"Allergic characteristics of urban schoolchildren with atopic eczema in Ghana","volume":"24","author":"Hogewoning","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4314\/pamj.v9i1.71210","article-title":"Atopic dermatitis in Tunisian schoolchildren","volume":"9","author":"Amouri","year":"2011","journal-title":"Pan Afr Med J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23937\/2572-3308.1510022","article-title":"Prevalence of skin allergies in adolescents in Namibia","volume":"3","author":"Mukesi","year":"2017","journal-title":"Int J Aller Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-015-0090-0","article-title":"Risk factors associated with asthma, atopic dermatitis and rhinoconjunctivitis in a rural Senegalese cohort","volume":"11","author":"Herrant","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s13555-022-00857-0","article-title":"Humanistic and economic burden of atopic dermatitis for adults and adolescents in the Middle East and Africa region","volume":"13","author":"Elezbawy","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clindermatol.2011.08.019","article-title":"Abnormal epidermal barrier in the pathogenesis of contact dermatitis","volume":"30","author":"Proksch","year":"2012","journal-title":"Clin Dermatol"},{"key":"B10","article-title":"Asteatotic eczema","volume-title":"StatPearls","author":"Specht","year":"2019"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1346-8138.1993.tb03820.x","article-title":"Quantitative analysis of stratum corneum lipids in xerosis and asteatotic eczema","volume":"20","author":"Akimoto","year":"1993","journal-title":"J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.4168\/aair.2014.6.4.276","article-title":"Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis","volume":"6","author":"Lee","year":"2014","journal-title":"Allergy Asthma Immunol Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/bjd.12957","article-title":"Atopic dermatitis\u2013all you can do from the outside","volume":"170","author":"Gelmetti","year":"2014","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jaci.2008.03.027","article-title":"Antimicrobial peptides and the skin immune defense system","volume":"122","author":"Schauber","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jaci.2005.12.1345","article-title":"Cathelicidin deficiency predisposes to eczema herpeticum","volume":"117","author":"Howell","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.immuni.2006.02.006","article-title":"Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus","volume":"24","author":"Howell","year":"2006","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jaci.2011.10.042","article-title":"IL-31 regulates differentiation and filaggrin expression in human organotypic skin models","volume":"129","author":"Cornelissen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/j.0022-202X.2005.23651.x","article-title":"Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-\u03b1 and interferon-\u03b3 in human epidermis","volume":"124","author":"Hatano","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1016\/j.jaci.2009.07.012","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"124","author":"Howell","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/jid.2011.24","article-title":"TNF-\u03b1 downregulates filaggrin and loricrin through c-jun N-terminal kinase: role for TNF-\u03b1 antagonists to improve skin barrier","volume":"131","author":"Kim","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.iac.2006.05.005","article-title":"Mast cell mediators in allergic inflammation and mastocytosis","volume":"26","author":"Castells","year":"2006","journal-title":"Immunol Allergy Clin"},{"key":"B23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1365-2222.1993.tb00308.x","article-title":"Histamine content, synthesis and degradation in human nasal mucosa","volume":"23","author":"Abe","year":"1993","journal-title":"Clin Exp Allergy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1006\/meth.1997.0494","article-title":"Markers of mast cell degranulation","volume":"13","author":"Hogan","year":"1997","journal-title":"Methods"},{"key":"B25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/all.12051","article-title":"Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model","volume":"68","author":"Gschwandtner","year":"2013","journal-title":"Allergy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/bjd.13199","article-title":"The histamine-synthesizing enzyme histidine decarboxylase is upregulated by keratinocytes in atopic skin","volume":"171","author":"Gutowska-Owsiak","year":"2014","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11882-014-0433-9","article-title":"Skin barrier defects in atopic dermatitis","volume":"14","author":"Agrawal","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.51866\/rv1141","article-title":"Prick, patch or blood test? A simple guide to allergy testing","volume":"16","author":"Muthupalaniappen","year":"2021","journal-title":"Malays Fam Physician"},{"key":"B29","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1590\/abd1806-4841.20132323","article-title":"Patch tests","volume":"88","author":"Lazzarini","year":"2013","journal-title":"An Bras Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/bjd.15239","article-title":"British Association of Dermatologists\u2019 guidelines for the management of contact dermatitis 2017","volume":"176","author":"Johnston","year":"2017","journal-title":"Br J Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2045-7022-3-3","article-title":"The skin prick test\u2014European standards","volume":"3","author":"Heinzerling","year":"2013","journal-title":"Clin Transl Allergy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s13555-022-00819-6","article-title":"Burden of atopic dermatitis in adults and adolescents: a systematic literature review","volume":"12","author":"Fasseeh","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC phase three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9899.1000110","article-title":"Th2 cytokines and atopic dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J Clin Cell Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.clindermatol.2017.03.006","article-title":"Current and emerging concepts in atopic dermatitis pathogenesis","volume":"35","author":"Sullivan","year":"2017","journal-title":"Clin Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3390\/jcm4050858","article-title":"Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics","volume":"4","author":"Mansouri","year":"2015","journal-title":"J Clin Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cyto.2014.11.023","article-title":"New pathogenic and therapeutic paradigms in atopic dermatitis","volume":"73","author":"Malajian","year":"2015","journal-title":"Cytokine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/08923973.2021.1889583","article-title":"Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies","volume":"43","author":"Mandlik","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1201\/9781003108375-5","article-title":"Medicinal plants for eczema","volume-title":"Medicinal Plants for Cosmetics, Health and Diseases","author":"Nel","year":"2022"},{"key":"B40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5114\/pdia.2014.40920","article-title":"Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis","volume":"31","author":"Nedoszytko","year":"2014","journal-title":"Adv Dermatol Allergol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"12851","DOI":"10.1073\/pnas.1818879115","article-title":"Molecular link between itch and atopic dermatitis","volume":"115","author":"Voisin","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12016-021-08875-0","article-title":"Contact dermatitis: classifications and management","volume":"61","author":"Li","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B43","first-page":"249","article-title":"Diagnosis and management of contact dermatitis","volume":"82","author":"Usatine","year":"2010","journal-title":"Am Fam Physician"},{"key":"B44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/ACI.0000000000000621","article-title":"Mechanism and diagnosis of protein contact dermatitis","volume":"20","author":"Barbaud","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jaad.2020.01.036","article-title":"Cannabinoids for the treatment of chronic pruritus: a review","volume":"82","author":"Avila","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1564528","DOI":"10.3389\/falgy.2025.1564528","article-title":"Scratching the surface: biomarkers and neurobiomarkers for improved allergic contact dermatitis management","volume":"6","author":"Sasaki","year":"2025","journal-title":"Front Allergy"},{"key":"B47","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/biomedicines13030656","article-title":"Neurogenic inflammation in allergic contact dermatitis","volume":"13","author":"Aitella","year":"2025","journal-title":"Biomedicines"},{"key":"B48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2310\/6620.2006.05021","article-title":"Dyshidrosis: epidemiology, clinical characteristics, and therapy","volume":"17","author":"Lofgren","year":"2006","journal-title":"Dermatitis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.mpmed.2025.04.012","article-title":"Non-atopic dermatitis","volume":"53","author":"Orton","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"176","DOI":"10.23937\/2474-3682\/1510176","article-title":"Dyshidrotic eczema: difficulty of etiological diagnosis and therapeutic management","volume":"7","author":"Belmourida","year":"2021","journal-title":"Clin Med Image Libr"},{"key":"B51","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0536.2008.01469.x","article-title":"Low-cobalt diet for dyshidrotic eczema patients","volume":"59","author":"Stuckert","year":"2008","journal-title":"Contact Dermatitis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.2147\/CIA.S65448","article-title":"N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients","volume":"9","author":"Yuan","year":"2014","journal-title":"Clin Interv Aging"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.3390\/ijms24055001","article-title":"Molecular mechanisms of neurogenic inflammation of the skin","volume":"24","author":"Marek-Jozefowicz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B54","volume-title":"Trait\u00e9 Pratique des Maladies de la Peau","author":"Devergie","year":"1854"},{"key":"B55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.24075\/brsmu.2018.006","article-title":"Clinical manifestations and immunology of nummular eczema","volume":"7","author":"Udzhuhu","year":"2018","journal-title":"Bull Russ State Med Univ"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/j.jemermed.2011.05.031","article-title":"Nummular eczema","volume":"43","author":"Halberg","year":"2012","journal-title":"J Emerg Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cyto.2015.01.030","article-title":"Interleukin 12 (IL-12) family cytokines: role in immune pathogenesis and treatment of CNS autoimmune disease","volume":"75","author":"Sun","year":"2015","journal-title":"Cytokine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/1573395054065115","article-title":"Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression","volume":"1","author":"Liu","year":"2005","journal-title":"Curr Immunol Rev"},{"key":"B59","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/cmi.2010.21","article-title":"Interleukin-17 and its expanding biological functions","volume":"7","author":"Xu","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.4049\/jimmunol.180.9.5771","article-title":"IL-10: the master regulator of immunity to infection","volume":"180","author":"Couper","year":"2008","journal-title":"J Immunol"},{"key":"B61","first-page":"185","article-title":"Diagnosis and treatment of seborrheic dermatitis","volume":"91","author":"Clark","year":"2015","journal-title":"Am Fam Physician"},{"key":"B62","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jamadermatol.2024.1987","article-title":"The global prevalence of seborrheic dermatitis: a systematic review and meta-analysis","volume":"160","author":"Polaskey","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1468-3083.2004.00693.x","article-title":"Seborrheic dermatitis","volume":"18","author":"Gupta","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B64","first-page":"125","article-title":"Seborrheic dermatitis: an overview","volume":"74","author":"Schwartz","year":"2006","journal-title":"Am Fam Physician"},{"key":"B65","volume-title":"Malassezia Furfur","author":"Vest","year":"2023"},{"key":"B66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2230.1991.tb00395.x","article-title":"An immunological study in patients with seborrhoeic dermatitis","volume":"16","author":"Bergbrant","year":"1991","journal-title":"Clin Exp Dermatol"},{"key":"B67","first-page":"333","article-title":"Safe and effective treatment of seborrheic dermatitis","volume":"83","author":"Elewski","year":"2009","journal-title":"Cutis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0733-8635(03)00028-7","article-title":"Seborrheic dermatitis","volume":"21","author":"Gupta","year":"2003","journal-title":"Dermatol Clin"},{"key":"B69","volume-title":"Dermatology","author":"Bolognia","year":"2012"},{"key":"B70","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1574-695X.2000.tb01471.x","article-title":"Enhancement of IL-8 production from human monocytic and granulocytic cell lines, THP-1 and HL-60, stimulated with Malassezia furfur","volume":"28","author":"Suzuki","year":"2000","journal-title":"FEMS Immunol Med Microbiol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1038\/jid.1995.13","article-title":"The interleukin-1 axis and cutaneous inflammation","volume":"105","author":"Kupper","year":"1995","journal-title":"J Invest Dermatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nri910","article-title":"NF-\u03baB regulation in the immune system","volume":"2","author":"Li","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0140-6736(91)92168-2","article-title":"Keratinocytes as initiators of inflammation","volume":"337","author":"Barker","year":"1991","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the national eczema association","volume":"137","author":"Drucker","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.anai.2018.12.017","article-title":"The socioeconomics of atopic dermatitis","volume":"122","author":"Chung","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2165\/00019053-200523060-00003","article-title":"The economics of topical immunomodulators for the treatment of atopic dermatitis","volume":"23","author":"Abramovits","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"B77","author":"Young","year":"2016"},{"key":"B78","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2340\/00015555-3102","article-title":"Out-of-pocket costs for individuals with atopic eczema: a cross-sectional study in nine European countries","volume":"99","author":"Zink","year":"2019","journal-title":"Acta Derm-Venereol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/cod.14007","article-title":"Characterizing demographics and cost of care for dyshidrotic eczema","volume":"86","author":"Gladys","year":"2022","journal-title":"Contact Dermatitis"},{"key":"B80","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/sj.bjp.0706736","article-title":"How corticosteroids control inflammation: quintiles prize lecture 2005","volume":"148","author":"Barnes","year":"2006","journal-title":"Br J Pharmacol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4103\/0378-6323.178903","article-title":"Topical corticosteroids in dermatology","volume":"82","author":"Mehta","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1093\/rheumatology\/keh333","article-title":"Corticosteroid resistance in rheumatoid arthritis: molecular and cellular perspectives","volume":"43","author":"Chikanza","year":"2004","journal-title":"Rheumatology"},{"key":"B83","first-page":"337","article-title":"Topical corticosteroids: choice and application","volume":"103","author":"Stacey","year":"2021","journal-title":"Am Fam Physician"},{"key":"B84","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1001\/jamadermatol.2022.1706","article-title":"Agreement and correlation between different topical corticosteroid potency classification systems","volume":"158","author":"Bowie","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2005.07.059","article-title":"Azathioprine in dermatology: the past, the present, and the future","volume":"55","author":"Patel","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2133.1986.tb02782.x","article-title":"Reduction in murine langerhans cell ATPase staining following topical but not systemic treatment with steroid and non-steroid immunosuppressants","volume":"114","author":"Halliday","year":"1986","journal-title":"Br J Dermatol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/09546630310016826","article-title":"Mycophenolate in dermatology","volume":"14","author":"Liu","year":"2003","journal-title":"J Dermatolog Treat"},{"key":"B88","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1046\/j.1365-2133.2000.03667.x","article-title":"Treatment of atopic eczema with oral mycophenolate mofetil","volume":"143","author":"Neuber","year":"2000","journal-title":"Br J Dermatol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(96)10310-X","article-title":"Mycophenolate mofetil","volume":"348","author":"Lipsky","year":"1996","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/bjd\/ljad281","article-title":"Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial","volume":"189","author":"Flohr","year":"2023","journal-title":"Br J Dermatol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1468-3083.2006.02023.x","article-title":"Cyclosporin in the treatment of patients with atopic eczema\u2013a systematic review and meta-analysis","volume":"21","author":"Schmitt","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"Br J Dermatol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.clindermatol.2016.05.011","article-title":"Phototherapy for atopic dermatitis","volume":"34","author":"Rodenbeck","year":"2016","journal-title":"Clin Dermatol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.abd.2021.03.001","article-title":"Phototherapy","volume":"96","author":"Barros","year":"2021","journal-title":"An Bras Dermatol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/00015550510025579","article-title":"Phototherapy with narrowband vs broadband UVB","volume":"85","author":"Berneburg","year":"2005","journal-title":"Acta Derm-Venereol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/sj.jidsp.5640185","article-title":"Mechanisms of ultraviolet (UV) B and UVA phototherapy","volume":"4","author":"Krutmann","year":"1999","journal-title":"J Investig Dermatol Symp Proc"},{"key":"B98","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.1008797","article-title":"Phototherapy in atopic dermatitis management","volume-title":"Atopic Dermatitis\u2014Bridging the Gap Between Clinical Science and Practical Care","author":"Molla","year":"2025"},{"key":"B99","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40629-025-00340-0","article-title":"Biologics in the treatment of atopic dermatitis: approved active substances and monoclonal antibodies in advanced clinical trials","volume":"34","author":"Royeck","year":"2025","journal-title":"Allergo J Int"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/esmoopen-2017-000180","article-title":"Biologics and biosimilars: what, why and how?","volume":"2","author":"Chan","year":"2017","journal-title":"Eur Soc Med Oncol Open"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: first global approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"key":"B102","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"B103","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"12411","DOI":"10.1038\/s41598-023-39311-2","article-title":"Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4R\u03b1, for the treatment of Th2 inflammatory diseases","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci Rep"},{"key":"B105","doi-asserted-by":"publisher","first-page":"6925","DOI":"10.3390\/jcm13226925","article-title":"Anti-OX40 biological therapies in the treatment of atopic dermatitis: a comprehensive review","volume":"13","author":"Marfil-Cant\u00f3n","year":"2024","journal-title":"J Clin Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10555-024-10184-9","article-title":"OX40\/OX40 Ligand and its role in precision immune oncology","volume":"43","author":"Thapa","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"B107","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40521-024-00374-9","article-title":"Immunological advancements in hand eczema treatment: progress with small molecules and biologics","volume":"11","author":"Grafanaki","year":"2024","journal-title":"Curr Treat Options Allergy"},{"key":"B108","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/10600280221103282","article-title":"Review of ruxolitinib in the treatment of atopic dermatitis","volume":"57","author":"Mohney","year":"2023","journal-title":"Ann Pharmacother"},{"key":"B109","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/cod.14303","article-title":"Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: results from the hand eczema symptom diary in a phase IIb randomized clinical trial","volume":"89","author":"Bauer","year":"2023","journal-title":"Contact Dermatitis"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2147\/JAA.S342051","article-title":"Management of atopic dermatitis: clinical utility of ruxolitinib","volume":"15","author":"Owji","year":"2022","journal-title":"J Asthma Allergy"},{"key":"B111","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bjd.17932","article-title":"The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study","volume":"181","author":"Bissonnette","year":"2019","journal-title":"Br J Dermatol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jaad.2023.04.027","article-title":"Oral spleen tyrosine kinase\/Janus kinase inhibitor gusacitinib for the treatment of chronic hand eczema: results of a randomized phase 2 study","volume":"89","author":"Jimenez","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.3390\/jcm11154431","article-title":"The JAK\/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic review","volume":"11","author":"Tsiogka","year":"2022","journal-title":"J Clin Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1111\/jdv.19194","article-title":"Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials","volume":"37","author":"Simpson","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/10600280221096713","article-title":"Abrocitinib: a new FDA-approved drug for moderate-to-severe atopic dermatitis","volume":"57","author":"Perche","year":"2023","journal-title":"Ann Pharmacother"},{"key":"B116","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"B117","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/jdv.19669","article-title":"Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by eczema area and severity Index (EASI) clinical subscores","volume":"38","author":"Wollenberg","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0140-6736(05)71227-7","article-title":"Complementary and alternative medicine","volume":"357","author":"Ernst","year":"2001","journal-title":"Lancet"},{"key":"B119","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1590\/S1516-05722014000200019","article-title":"Phytotherapy: an introduction to its history, use and application","volume":"16","author":"Ferreira","year":"2014","journal-title":"Rev Bras Plantas Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.pop.2017.02.001","article-title":"Phytotherapy: an introduction to herbal medicine","volume":"44","author":"Falzon","year":"2017","journal-title":"Primary Care Clin Office Pract"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(08)61354-9","article-title":"Traditional Chinese medicine","volume":"372","author":"Tang","year":"2008","journal-title":"Lancet"},{"key":"B122","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/09546630510038938","article-title":"A survey of traditional Chinese medicine use in children with atopic dermatitis attending a paediatric dermatology clinic","volume":"16","author":"Hon","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"B123","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1749-8546-6-17","article-title":"Chinese Herbal medicine research in eczema treatment","volume":"6","author":"Hon","year":"2011","journal-title":"Chin Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.3390\/molecules23112776","article-title":"Anti-inflammatory activities of pentaherbs formula and its influence on gut microbiota in allergic asthma","volume":"23","author":"Tsang","year":"2018","journal-title":"Molecules"},{"key":"B125","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2133.2007.07941.x","article-title":"Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study","volume":"157","author":"Hon","year":"2007","journal-title":"Br J Dermatol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"59","DOI":"10.56782\/pps.215","article-title":"Traditional use of chamomile flowers (Matricariae flos) in inflammatory-associated skin disorders","volume":"22","author":"Melnyk","year":"2024","journal-title":"Prospect Pharm Sci"},{"key":"B127","doi-asserted-by":"publisher","first-page":"706836","DOI":"10.3389\/fphar.2021.706836","article-title":"The mechanism action of German chamomile (Matricaria recutita L.) in the treatment of eczema: based on dose\u2013effect weight coefficient network pharmacology","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"170","DOI":"10.5114\/pdia.2013.35620","article-title":"Medicinal plants used in treatment of inflammatory skin diseases","volume":"30","author":"Dawid Pa\u0107","year":"2013","journal-title":"Adv Dermatol Allergol\/Post Dermatol Alergol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1046\/j.1529-8019.2003.01624.x","article-title":"Complementary therapy for atopic eczema and other allergic skin diseases","volume":"16","author":"Artik","year":"2003","journal-title":"Dermatol Ther"},{"key":"B130","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0041-008X(03)00301-6","article-title":"Cyclooxygenases in the skin: pharmacological and toxicological implications","volume":"192","author":"Lee","year":"2003","journal-title":"Toxicol Appl Pharmacol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF01967296","article-title":"Effect of a 5-lipoxygenase (5-LO)\/cyclooxygenase (CO) inhibitor, WY-47, 288, on cutaneous models of inflammation","volume":"26","author":"Carlson","year":"1989","journal-title":"Agents Actions"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/j.1600-0625.2008.00786.x","article-title":"The skin: an indispensable barrier","volume":"17","author":"Proksch","year":"2008","journal-title":"Exp Dermatol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.3390\/plants12203532","article-title":"Arnica Montana L.: doesn\u2019t origin matter?","volume":"12","author":"Schmidt","year":"2023","journal-title":"Plants"},{"key":"B134","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/jphp.12724","article-title":"Arnica Montana L.\u2013a plant of healing","volume":"69","author":"Kriplani","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijbiomac.2014.05.051","article-title":"Characterization and pharmacodynamic properties of Arnica Montana complex","volume":"69","author":"\u0160utovsk\u00e1","year":"2014","journal-title":"Int J Biol Macromol"},{"key":"B136","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/1-4020-5449-1_14","article-title":"Conservation of eastern-European medicinal plants: Arnica Montana in Romania","author":"Kathe","year":"2006","journal-title":"Medicinal and Aromatic Plants: Agricultural, Commercial, Ecological, Legal, Pharmacological and Social Aspects. Wageningen UR Frontis Series"},{"key":"B137","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.indcrop.2013.10.035","article-title":"Morphological and chemical characterization of Arnica Montana L. Under different cultivation models","volume":"52","author":"Pljevljaku\u0161i\u0107","year":"2014","journal-title":"Ind Crops Prod"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.5897\/SRE11.630","article-title":"Pot marigold (Calendula officinalis) medicinal usage and cultivation","volume":"7","author":"moghaddasi Mohammad","year":"2012","journal-title":"Sci Res Essays"},{"key":"B139","doi-asserted-by":"publisher","first-page":"ZE23","DOI":"10.7860\/JCDR\/2022\/52195.16024","article-title":"A review of Calendula Officinalis-magic in science","volume":"16","author":"Patil","year":"2022","journal-title":"J Clin Diagn Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.aca.2013.08.048","article-title":"Qualitative and quantitative high performance thin layer chromatography analysis of Calendula officinalis using high resolution plate imaging and artificial neural network data modelling","volume":"798","author":"Agatonovic-Kustrin","year":"2013","journal-title":"Anal Chim Acta"},{"key":"B141","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/j.1365-4632.2012.05777.x","article-title":"Clinical-epidemiological features of contact dermatitis in rural and urban communities in northern Ethiopia: correlation with environmental or occupational exposure","volume":"53","author":"Morrone","year":"2014","journal-title":"Int J Dermatol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"10","DOI":"10.12788\/cutis.0292","article-title":"Update on contact dermatitis and patch testing in patients with skin of color","volume":"108","author":"Scott","year":"2021","journal-title":"Cutis"},{"key":"B143","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1600-0781.2004.00092.x","article-title":"Photoallergic contact dermatitis","volume":"20","author":"Goossens","year":"2004","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"B144","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/DER.0b013e31827edc8b","article-title":"Allergic and photoallergic contact dermatitis: a 10-year experience","volume":"24","author":"Greenspoon","year":"2013","journal-title":"Dermatitis"},{"key":"B145","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1046\/j.1365-2230.2003.01378.x","article-title":"A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema","volume":"28","author":"Polderman","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0140-6736(91)90083-2","article-title":"PUVA And cancer: a large-scale epidemiological study","volume":"338","author":"Lindel\u00f6f","year":"1991","journal-title":"Lancet"},{"key":"B147","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jaad.2021.11.048","article-title":"Incidence of skin cancers in patients with eczema treated with ultraviolet phototherapy","volume":"87","author":"Ahad","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1600-0560.2007.00861.x","article-title":"Evaluation of Langerhans\u2019 cells in normal and eczematous dermatitis skin by CD1a protein immunohistochemistry: preliminary findings","volume":"35","author":"Hussein","year":"2008","journal-title":"J Cutan Pathol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/00007890-199603150-00008","article-title":"The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study","volume":"61","author":"Bavinck","year":"1996","journal-title":"Transplantation"},{"key":"B150","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1172\/JCI107031","article-title":"The effect of azathioprine on gammaglobulin synthesis in man","volume":"51","author":"Levy","year":"1972","journal-title":"J Clin Invest"},{"key":"B151","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s004030050098","article-title":"Effects of pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN\u03b3) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis","volume":"288","author":"Neuber","year":"1996","journal-title":"Arch Dermatol Res"},{"key":"B152","doi-asserted-by":"publisher","first-page":"570","DOI":"10.4049\/jimmunol.144.2.570","article-title":"IL-4 inhibits the synthesis of IFN-gamma and induces the synthesis of IgE in human mixed lymphocyte cultures","volume":"144","author":"Vercelli","year":"1990","journal-title":"J Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1001\/archderm.134.3.378","article-title":"Dyshidrotic eczema treated with mycophenolate mofetil","volume":"134","author":"Picken\u00e4cker","year":"1998","journal-title":"Arch Dermatol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"B155","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","article-title":"Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study","volume":"160","author":"Beck","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1458438","DOI":"10.3389\/fphar.2024.1458438","article-title":"Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1429709","DOI":"10.3389\/fphar.2024.1429709","article-title":"Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis","volume":"15","author":"Lin","year":"2024","journal-title":"Front Pharmacol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial","volume":"161","author":"St\u00e4nder","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"B160","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1007\/s13555-025-01492-1","article-title":"Rocatinlimab: a novel T-cell rebalancing therapy targeting the OX40 receptor in atopic dermatitis","volume":"15","author":"Guttman-Yassky","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaci.2023.11.924","article-title":"Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Ra, in adults with moderate to severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001)","volume":"153","author":"Silverberg","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"116149","DOI":"10.1016\/j.jep.2023.116149","article-title":"In vitro tests to evaluate embryotoxicity and irritation of Chinese herbal medicine (pentaherbs formulation) for atopic dermatitis","volume":"305","author":"Li","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/ptr.3617","article-title":"Berberine-induced haemolysis revisited: safety of Rhizoma coptidis and Cortex phellodendri in chronic haematological diseases","volume":"26","author":"Yc","year":"2012","journal-title":"Phytother Res"},{"key":"B165","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1034\/j.1600-0536.2001.450503.x","article-title":"The seamy side of natural medicines: contact sensitization to arnica (Arnica Montana L.) and marigold (Calendula officinalis L.)","volume":"45","author":"Reider","year":"2001","journal-title":"Contact Dermatitis"},{"key":"B166","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jpeds.2010.07.009","article-title":"Eczema in early life: genetics, the skin barrier, and lessons learned from birth cohort studies","volume":"157","author":"Myers","year":"2010","journal-title":"J Pediatr"},{"key":"B167","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jaci.2007.12.1161","article-title":"Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity","volume":"121","author":"Gupta","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1600-0536.2010.01730.x","article-title":"The coumarin herniarin as a sensitizer in German chamomile [Chamomilla recutita (L.) rauschert, Compositae]","volume":"62","author":"Paulsen","year":"2010","journal-title":"Contact Dermatitis"},{"key":"B169","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2310\/6620.2011.10118","article-title":"Compositae-associated allergic contact dermatitis from bisabolol","volume":"22","author":"Jacob","year":"2011","journal-title":"Dermatitis"},{"key":"B170","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2500\/aap.2012.33.3569","article-title":"Epidemiology of atopic dermatitis: a review","volume":"33","author":"DaVeiga","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"B171","first-page":"1","article-title":"Allergic contact dermatitis","volume-title":"Curr Dir Autoimmun","author":"Gober","year":"2008"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/exd.14054","article-title":"Itchy body: topographical difference of itch and scratching and C nerve fibres","volume":"28","author":"Hashimoto","year":"2019","journal-title":"Exp Dermatol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/08820139.2020.1775643","article-title":"Immunological role of IgG subclasses","volume":"50","author":"Napodano","year":"2021","journal-title":"Immunol Investig"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/jdv.20639","article-title":"European Guideline (EuroGuiDerm) on atopic eczema: living update","volume":"39","author":"Wollenberg","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/00015559850135814","article-title":"Long-term follow-up of eczema patients treated with cyclosporine","volume":"78","author":"Granlund","year":"1998","journal-title":"Acta Derm-Venereol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/all.12498","article-title":"Off-label prescriptions for atopic dermatitis in Europe","volume":"70","author":"Bieber","year":"2015","journal-title":"Allergy"},{"key":"B177","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"Cd013870","DOI":"10.1002\/14651858.CD013870.pub2","article-title":"Phototherapy for atopic eczema","volume":"10","author":"Musters","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/bjd.18959","article-title":"The European TREatment of ATopic eczema (TREAT) registry taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema","volume":"183","author":"Vermeulen","year":"2020","journal-title":"Br J Dermatol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1021\/np0105679","article-title":"(+)-epi-\u03b1-Bisabolol is the wound-healing principle of Peperomia galioides: investigation of the in vivo wound-healing activity of related terpenoids","volume":"65","author":"Villegas","year":"2002","journal-title":"J Nat Prod"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3390\/nu14071370","article-title":"Health benefits, pharmacological effects, molecular mechanisms, and therapeutic potential of \u03b1-bisabolol","volume":"14","author":"Eddin","year":"2022","journal-title":"Nutrients"},{"key":"B182","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1468-3083.2010.03950.x","article-title":"Effect of topical heparin and levomenol on atopic dermatitis: a randomized four-arm, placebo-controlled, double-blind clinical study","volume":"25","author":"Arenberger","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.plefa.2015.11.006","article-title":"Apigenin inhibits COX-2, PGE2, and EP1 and also initiates terminal differentiation in the epidermis of tumor bearing mice","volume":"104","author":"Kiraly","year":"2016","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"B184","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000078498","article-title":"Flavonoids such as luteolin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by ActivatedHuman basophils","volume":"134","author":"Hirano","year":"2004","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1248\/bpb.29.64","article-title":"Caffeic acid inhibits compound 48\/80-induced allergic symptoms in mice","volume":"29","author":"Hossen","year":"2006","journal-title":"Biol Pharm Bull"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6882-12-93","article-title":"NF-\u03baB p65 repression by the sesquiterpene lactone, helenalin, contributes to the induction of autophagy cell death","volume":"12","author":"Lim","year":"2012","journal-title":"BMC Complement Altern Med"},{"key":"B187","doi-asserted-by":"publisher","first-page":"219","DOI":"10.36468\/pharmaceutical-sciences.767","article-title":"Evaluation of real time cell proliferation, anti-inflammatory and wound healing potential of helenalin on HaCaT keratinocytes treated with lipopolysaccharide stimulated monocytes","volume":"83","author":"Yuksel","year":"2021","journal-title":"Indian J Pharm Sci"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1675475\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:17:31Z","timestamp":1768205851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1675475\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":187,"alternative-id":["10.3389\/falgy.2025.1675475"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1675475","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1675475"}}